Side-by-Side Comparison of the In Vivo Performance of [ 212 Pb]Pb-DOTAMTATE and Other SSTR2-Targeting Compounds
Journal of Nuclear Medicine · 2025
DOI: 10.2967/jnumed.124.268345 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Journal of Nuclear Medicine, 2025. Verfasst von Amal Saidi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Orano Med SAS, Paris, France; and amal.saidi@oranomed.com. Hauptthemen laut MEDLINE: Receptors, Somatostatin, Lead Radioisotopes, Organometallic Compounds. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
There are numerous versions of octreotide and octreotate, including DOTAMTATE, DOTATATE, JR11, and lead-specific chelator (PSC)-PEG2-TOC. These peptides, which can be either analogs or antagonists, are used in nuclear medicine for diagnostic imaging or targeted radionuclide therapy of neuroendocrine tumors that are positive for somatostatin receptors (SSTRs). Despite their structural and targeting similarities, they have distinct properties and clinical uses. We aimed to perform an extensive preclinical comparison of all these somatostatin analogs with 212Pb, directly studying their pharmacokinetic properties in tumors overexpressing SSTR2.
Methods
All SSTR2 analogs were manufactured with the DOTAM, PSC, or DOTA chelators for appropriate comparison after radiolabeling with 212Pb. Chelation, quantification, and pharmacokinetics were compared side by side in AR42J-tumor–bearing animals.
Results
These findings highlight the superior chelation efficiency and faster kinetics of DOTAM and then DOTA compared with the PSC. We also discovered a superior tumor-to-kidney area under the curve ratio for [212Pb]Pb-DOTAMTATE over other SSTR2-targeting peptides when radiolabeled with 212Pb.
Conclusion
Taken together, the results indicates that [212Pb]Pb-DOTAMTATE has favorable tumor retention and a more favorable dosimetry profile, which is crucial for targeted α-therapy in treating SSTR2-positive neuroendocrine tumors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Orano Med SAS, Paris, France; and amal.saidi@oranomed.com.
- Orano Med LLC, Plano, Texas.
- Orano Med SAS, Paris, France; and.
Zitieren
APA
Saidi, A., Stallons, T. A., Wong, A. G., Schatzmann, A. T., Soysal, U., & Torgue, J. J. (2025). Side-by-Side Comparison of the In Vivo Performance of [ 212 Pb]Pb-DOTAMTATE and Other SSTR2-Targeting Compounds. Journal of Nuclear Medicine. https://doi.org/10.2967/jnumed.124.268345
Vancouver
Saidi A, Stallons TA, Wong AG, Schatzmann AT, Soysal U, Torgue JJ. Side-by-Side Comparison of the In Vivo Performance of [ 212 Pb]Pb-DOTAMTATE and Other SSTR2-Targeting Compounds. Journal of Nuclear Medicine. 2025. doi:10.2967/jnumed.124.268345
BibTeX
@article{Saidi2025,
author = {Saidi, Amal and Stallons, Tania A and Wong, Amy G and Schatzmann, Aaron T and Soysal, Ugur and Torgue, Julien J},
title = {Side-by-Side Comparison of the In Vivo Performance of [ 212 Pb]Pb-DOTAMTATE and Other SSTR2-Targeting Compounds},
journal = {Journal of Nuclear Medicine},
year = {2025},
doi = {10.2967/jnumed.124.268345}
}
EUVIMED